28 January 2025
Biopharmaceuticals
Industry News
Investments
Umoja Biopharma, a US biotech company focused on the development of immunotherapy treatments of cancerous cells, has raised $100 million in a Series C funding round, co-led by DCVC bio and Doiuble Point Ventures, with involvement from other new and existing life-science investors.
The funds will be used to enable Umoja to progress its in vivo CAR T cell therapy pipeline, namely its leading CD22 UB-VV400 program in many autoimmunology and oncology clinical studies.